Recent histone deacetylase inhibitors in cancer therapy
Open accessAbstract
Cancer metastasis increases the complexity of the disease and escalates patient mortality. Traditional chemotherapy has been associated with low efficacy and marked side effects. Studies pivot toward histone deacetylase (HDAC) enzymes and inhibitors because they are critical for chromatin structure, gene regulation, and cellular activities that are linked to metastasis and cancer progression. HDAC inhibitors (HDACi) can alter gene expression patterns and can lead to cell‐cycle arrest and apoptosis in neoplastic cells. Several HDACi drugs like vorinostat, romidepsin, panobinostat, and belinostat are approved by the Food and Drug Administration. China and Japan have approved the use of tucidinostat, a new subtype‐selective HDACi that inhibits class 1 HDAC1, HDAC2, HDAC3, as well as class 2b HDAC10. These drugs have shown promising results in the treatment of multiple carcinoma including cervical cancer, T‐cell lymphoma, brain cancer, and breast cancer. This review highlights the HDACi classes, the mechanism of action of these inhibitors, their preclinical and clinical efficacy, and the latest clinical trials and patents used in cancer therapeutics. Overall, this review focuses on patents and clinical trials data from 2019 onward to give a better viewpoint on current trends in HDACis as chemotherapy agents.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Various KDAC inhibitors have been approved by the FDA, such as vorinostat and romidepsin, but there are currently no approved KAT inhibitors.
“Various KDAC inhibitors [19] have been approved by the FDA such as vorinostat [20] (commonly known as SAHA) and romidepsin [21], but there are currently no approved KAT inhibitors [22–24].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · see citing works
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795 · see citing works
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676 · see citing works
Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 671 · see citing works
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 440 · see citing works
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Guo, L., Tian, Y., & Zhu, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 358 · see citing works
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 358 · see citing works
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
McClure, J. J., Li, X., & Chou, C. J. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.006 · Cited by 356 · see citing works
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 330 · see citing works
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C. M., Rahman, F., Piekarz, R., Peer, C. J., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 294 · see citing works
HDAC Inhibitors in Acute Myeloid Leukemia
José‐Eneriz, E. S., Gimenez-Camino, N., Agirre, X., & Prósper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 228 · see citing works
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 224 · see citing works
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197 · see citing works
Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. M., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 194 · see citing works
HDAC11: a rising star in epigenetics
Liu, S., Wu, F., Jin, Y., Weiqin, C., & Xu, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110607 · Cited by 116 · see citing works
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 92 · see citing works
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Zhou, M., Yuan, M., Zhang, M., Lei, C., Aras, O., Zhang, X., & An, F. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113825 · Cited by 92 · see citing works
Liu, J.-R., Yu, C., Hung, P.-Y., Hsin, L., & Chern, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 83 · see citing works
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
Huang, M., Zhang, J., Yan, C., Li, X., Zhang, J., & Ling, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103184 · Cited by 79 · see citing works
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., & Le Tourneau, C. (2021) · Cancers · doi:10.3390/cancers14010066 · Cited by 75 · see citing works
Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression
Hu, Z.-L., Wei, F., Su, Y., Yf, W., Shen, Y., Fang, Y., Ding, J., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01221-6 · Cited by 73 · see citing works
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Gong, P., Wang, Y., & Jing, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071601 · Cited by 69 · see citing works
Zhang, S., Fujita, Y., Matsuzaki, R., & Yamashita, T. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0543-8 · Cited by 68 · see citing works
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 67 · see citing works
Wang, H., Liu, Y.-C., Zhu, C.-Y., Yan, F., Wang, M.-Z., Chen, X., Wang, X.-K., Pang, B., Li, Y.-H., Liu, D.-H., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01792-8 · Cited by 57 · see citing works
Teknos, T. N., Grecula, J. C., Agrawal, A., Old, M. O., Ozer, E., Carrau, R., Kang, S.-Y., Rocco, J. W., Blakaj, D. M., Diavolitsis, V. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0696-4 · Cited by 50 · see citing works
HDAC3 functions as a positive regulator in Notch signal transduction
Ferrante, F., Giaimo, B. D., Bartkuhn, M., Zimmermann, T., Close, V., Mertens, D., Nist, A., Stiewe, T., Meier-Soelch, J., Kracht, M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa088 · Cited by 50 · see citing works
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2020) · Molecules · doi:10.3390/molecules25194394 · Cited by 47 · see citing works
Santos‐Barriopedro, I., Li, Y., Bahl, S., & Seto, E. (2019) · Genes & Cancer · doi:10.18632/genesandcancer.197 · Cited by 41 · see citing works
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 41 · see citing works
Urdiciain, A., Erausquin, E., Mel�ndez, B., REY, J. A., Idoate, M. A., & Castresana, J. S. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4739 · Cited by 40 · see citing works
Vu, K., Wu, C.-H., Yang, C., Zhan, A., Cavallone, E., Berry, W., Heeter, P., Pincus, L. B., Wieduwilt, M. J., William, B. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2152 · Cited by 40 · see citing works
Ranganna, K., Selvam, C., Shivachar, A. C., & Yousefipour, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218198 · Cited by 39 · see citing works
Duvic, M. A., Bates, S. E., Piekarz, R., Eisch, R. A., Kim, Y. H., Lerner, A., Robak, T., Samtsov, A. V., Becker, J. C., McCulloch, W. F., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361022 · Cited by 35 · see citing works
Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension
Kee, H. J., Kim, I., & Jeong, M. H. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115111 · Cited by 35 · see citing works
Hsu, K., Huang, C., Tam, K., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020452 · Cited by 32 · see citing works
Homan, M. J., Franson, A. T., Ravi, K., Roberts, H. J., Pai, M. P., Liu, C., He, M., Matvekas, A., Koschmann, C. J., & Marini, B. L. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04313-2 · Cited by 30 · see citing works
Cao, F., Zwinderman, M. R. H., van Merkerk, R., Ettema, P. E., Quax, W. J., & Dekker, F. J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.038 · Cited by 23 · see citing works
Liu, W., Zhao, D., Liu, T., Niu, T., Song, Y., Xu, W., Jin, J., Cai, Q., Huang, H., Li, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750323 · Cited by 21 · see citing works
The therapeutic properties of resminostat for hepatocellular carcinoma
Zhao, J., Gray, S. G., Wabitsch, M., et al. (2018) · Oncoscience · doi:10.18632/oncoscience.420 · Cited by 13 · see citing works
Clinical Applications of Histone Deacetylase Inhibitors
Park, J., Terranova-Barberio, M., Zhong, A. Y., Thomas, S., & Münster, P. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805388-1.00040-7 · Cited by 12 · see citing works
Zhang, N., Sun, P., Jin, H., et al. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000935 · Cited by 10 · see citing works
Design, Synthesis and Evaluation of Belinostat Analogs as Histone Deacetylase Inhibitors
Zhang, J., Mottamal, M., Jin, H., et al. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0587 · Cited by 9 · see citing works
Histone Deacetylase Inhibitors in Medical Therapeutics
Chun, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00034-x · Cited by 8 · see citing works
HDAC inhibitors in liver cancer: which route to take?
Kiesslich, T., & Neureiter, D. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1605289 · Cited by 7 · see citing works
Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 5 · see citing works
Sun, H., Song, J., Sun, M., & Shan, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823684-0.00014-1 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- Kwon Y, Kim Y, Jung H, Jeoung D. Role of HDAC3-miRNA-CAGE network in anti-cancer drug-resistance. Int J Mol Sci. 2018;20(1): 51. doi:10.3390/ijms2001005 · DOI
- Kozloff MF, Berlin J, Flynn PJ, et al Randomized phase II trial of tucidinostat plus FOLFOX in patients with metastatic colorectal cancer refractory to standard therapies. Clin Cancer Res. 2021;27(2): 324-332.
- West AC, Johnstone RW, Newbold A. Histone deacetylase in- hibitors: current status and perspectives. Int J Biochem Cell Biol. 2019;116:105642.
Cited by
Sorted by citations
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20 · see citing works
- Authors
- Parveen, R., Harihar, D., & Chatterji, B. P.
- Affiliations
- Tampere University (FI)
- KTH Royal Institute of Technology (SE)
- Assam Down Town University (IN)
- Corresponding author
- Chatterji, Biswa Prasun
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2023-08-10
- Volume
- 129
- Issue
- 21
- Pages
- 3372-3380
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W4385716353
- Cited by
- 171
- References
- 47
- Citations by year
- 2026: 62 · 2025: 73 · 2024: 34 · 2023: 2
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, cancer therapy, vorinostat, romidepsin, panobinostat, belinostat, tucidinostat, chromatin regulation, apoptosis, cell cycle arrest, metastasis, cervical cancer, T-cell lymphoma, breast cancer, brain cancer, patents, clinical trials
- MeSH terms
- Animals, Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
